Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Feb 06, 2023 5:04pm
196 Views
Post# 35270409

RE:Waiting leads to worry, facts can help....

RE:Waiting leads to worry, facts can help....Companies that have something to sell and are negotiating with multiple parties who are interested in buying what they have to sell (i.e. the company) don't telegraph their intentions until the multi-party negotiations are completed and the deal is closed !

The same applies to the buyers, such as the Big Pharma companies who are not inclined to telegraph their overall intentions either.

Those seeking to detract on the various message baords have no direct part in the above process, and are more interested in getting the best price on the sellers stock ....

.... especially on a company that has a putative/speculative/potential M&A acquisition valuation of approximatley US$9-10 Billion for ONCY, as a bolt-on acquistion, which is a valuation that comfortably falls within Big Pharma's M&A "sweet spot" range of US$5-15 Billion.
<< Previous
Bullboard Posts
Next >>